½ÃÀ庸°í¼­
»óǰÄÚµå
1562240

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Àü¸Á(-2030³â) : Áö¿ªº° ºÐ¼® - À¯Çüº°, Ä¡·á¹ýº°, ¿¬·É´ëº°, ÃÖÁ¾ »ç¿ëÀÚº°

Asia Pacific Myopia Treatment Market Forecast to 2030 - Regional Analysis - by Type, Treatment, Age Group, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 107 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº 2022³â 30¾ï 9,716¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 63¾ï 4,864¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022-2030³â°£ 9.4%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ë»ó ±Ù½Ã Ä¡·á¸¦ À§ÇÑ Ã·´Ü ±â¼úÀÇ °¡¿ë¼º Áõ°¡·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ¼ºÀå ÃËÁø

±Ù½Ã¸¦ Ä¡·áÇÒ ¼ö Àִ ÷´Ü ±â¼úÀÌ Á¡Á¡ ´õ ¸¹ÀÌ °³¹ßµÇ°í ÀÖ´Â °ÍÀº ±Ù½Ã Ä¡·á ½ÃÀå¿¡ Å« ±âȸ°¡ µÉ °ÍÀÔ´Ï´Ù. ·¹ÀÌÀú º¸Á¶ ¿øÀ§ºÎ °¢¸· ÀýÁ¦¼ú(LASIK), ±¤±¼Àý °¢¸· ÀýÁ¦¼ú(PRK), Àΰø¼öÁ¤Ã¼ ¾È±¸ ³» ·»Áî(ICL)¿Í °°Àº ±â¼úÀÇ ¹ßÀüÀ¸·Î ±Ù½Ã¸¦ º¸´Ù È¿°úÀûÀ̰í ÇÕº´Áõ ¾øÀÌ ±³Á¤ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. 30°³ ÀÌ»óÀÇ ¿¬Á¦°¡ ¹ßÇ¥ ½ÂÀÎÀ» ¹Þ¾Ò½À´Ï´Ù. ¿Ü°ú ÀÇ»ç´Â Çõ½ÅÀûÀÎ SILK(Smooth Incision Lenticule Keratomileusis) Ä¡·á¹ýÀ» ³­½Ã°¡ ÀÖ´Â ±Ù½Ã ȯÀÚ Ä¡·á¿¡ Àû¿ëÇÒ ¼ö ÀÖÀ¸¸ç, ELITATM Ç÷§ÆûÀ» Ȱ¿ëÇÒ ¼ö ÀÖÀ¸¸ç, °í¼Ó ·¹ÀÌÀú Á¶»ç ±â¼ú°ú ÃÊÁ¤¹Ð ·¹ÀÌÀú ÆÞ½º¸¦ ÅëÇØ ¿Ü°ú Àǻ翡°Ô ¸Å¿ì ºÎµå·´°í °£ÆíÇÑ ¼öÁ¤Ã¼³¶ ÀýÁ¦¼úÀ» Á¦°øÇϸç, ´ÙÀ½³¯ Ä¡·á °á°ú¿Í ȸº¹ÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ±â¼úÀº ±âÁ¸¿¡´Â °í°¡¿©¼­ ¸¹Àº ȯÀڵ鿡°Ô Á¢±ÙÇϱ⠾î·Á¿ü½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ±â¼úÀÌ ´õ ³Î¸® º¸±ÞµÇ¸é ±Ù½Ã Ä¡·á ½ÃÀåÀÌ È®´ëµÇ¾î ´õ ¸¹Àº ȯÀڵ鿡°Ô ´õ ³ªÀº Ä¡·á ¿É¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ´Â ±âȸ°¡ µÉ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü ±â¼ú ¿Ü¿¡µµ, ±Ù½Ã¸¦ È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â »õ·Î¿î Ä¡·á¹ý Áß ÇϳªÀÎ Á¤À§°¢¸· Àý»è¼ú(Orthokeratology, Ortho-K)°ú ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦¿Í °°Àº »õ·Î¿î Ä¡·á¹ýµµ Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. Àαâ ÀÖ´Â ¿À¸£¼ÒÄɶóÅä·ÎÁö ÄÜÅÃÆ®·»Áî´Â ÄíÆÛºñÁ¯ÀÇ ÃֽŠ±Ù½Ã ¾ïÁ¦ Á¦Ç°À¸·Î CE ¸¶Å©¸¦ ȹµæÇÑ Á¦Ç°ÀÔ´Ï´Ù. ÀÌ Á¦Ç°Àº EyeDream°ú Paragon CRTÀÇ Á¤À§°¢¸· µðÀÚÀÎ, MiSightÀÇ µ¥ÀÌ ¼ÒÇÁÆ® ÄÜÅÃÆ®·»Áî, SightGlass VisionÀÇ È®»ê ±¤ÇÐ ±â¼ú ¾È°æ ·»Áî¿¡ ÇÕ·ùÇÏ°Ô µË´Ï´Ù. ÀÌ·¯ÇÑ ºñħ½ÀÀû Ä¡·á´Â ¼ö¼úÀû Ä¡·áº¸´Ù °¡°ÝÀÌ Àú·ÅÇϱ⠶§¹®¿¡ ´õ ¸¹Àº ȯÀÚµéÀÌ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î, ´ë»ó ±Ù½Ã¸¦ Ä¡·áÇÒ ¼ö Àִ ÷´Ü ±â¼úÀÇ °¡¿ë¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó ±Ù½Ã Ä¡·á ½ÃÀå¿¡ Å« ±âȸ°¡ µÇ°í ÀÖ½À´Ï´Ù. ȯÀڵ鿡°Ô º¸´Ù È¿°úÀûÀ̰í Á¢±ÙÇϱ⠽¬¿î Ä¡·á ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀåÀº ½Ã·Â °Ç°­ »óŸ¦ °³¼±Çϰí Àü ¼¼°è ÀÇ·á ȯ°æ¿¡¼­ Áß¿äÇÑ ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ãų ¼ö ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå °³¿ä

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, È£ÁÖ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. ÀÌ Áö¿ªÀº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀÇ 30.14% ÀÌ»óÀ» Â÷ÁöÇߴµ¥, ÀÌ´Â ÀÌ Áö¿ªÀÇ °í·ÉÈ­ Àα¸ Áõ°¡, ¿¬±¸ Á¶»ç Áõ°¡, Á¤ºÎ Áö¿ø Áõ°¡, ¾È°ú °ü·Ã Áúȯ Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­´Â Áß±¹ÀÌ 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀº Àα¸ °í·ÉÈ­, ±Ù½Ã À¯º´·ü Áõ°¡, ¿¹¹æ ÀÇ·á¿¡ ´ëÇÑ Á߿伺 Áõ°¡ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Àα¸¹®Á¦¿¬±¸¼Ò°¡ 2020³â¿¡ ¹ßÇ¥ÇÑ ¿¬±¸¿¡ µû¸£¸é Áß±¹ÀÇ ³ë·É Àα¸´Â 2050³â±îÁö 3¾ï 6,600¸¸ ¸í¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ °°Àº Ã߻꿡 µû¸£¸é 2050³â±îÁö Áß±¹ Àα¸ÀÇ ¾à 26%°¡ 65¼¼ ÀÌ»óÀÌ µÉ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â 2020³âÀÇ 12%¿¡¼­ Áõ°¡ÇÑ ¼öÄ¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ³ë·É Àα¸ÀÇ ´ëÆøÀûÀÎ Áõ°¡´Â Áß±¹ ³» Á¦Ç° ¼ö¿ä Áõ°¡¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ Áß±¹¿¡¼­ ±Ù½Ã À¯º´·ü, ƯÈ÷ ¾î¸°ÀÌ ±Ù½Ã À¯º´·üÀÌ Å©°Ô Áõ°¡ÇÏ¿© Áß±¹¿¡¼­ Ä¡·á¹ý äÅÃÀÌ Áõ°¡ ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ¿¹¸¦ µé¾î, British Journal of Ophthalmology¿¡ µû¸£¸é 2019³â Áß±¹ ¹ÌÃëÇÐ ¾Æµ¿°ú ÃÊÁß°í»ýÀÇ ±Ù½Ã À¯º´·üÀº 50.2%¿¡ ´ÞÇß½À´Ï´Ù. ¶ÇÇÑ °°Àº ÀÚ·á¿¡ µû¸£¸é 2021³â¿¡´Â 6¼¼¿¡¼­ 16¼¼ »çÀÌÀÇ ¾î¸°ÀÌ¿Í Ã»¼Ò³âÀÇ 54.71%°¡ ±Ù½ÃÀÎ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀÌó·³ ³ëÀÎ Àα¸ Áõ°¡¿Í ±Ù½Ã À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ¼¼ºÐÈ­

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº À¯Çü, Ä¡·á¹ý, ¿¬·É´ë, ÃÖÁ¾ »ç¿ëÀÚ ¹× ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

À¯Çüº°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº °­µµ ±Ù½Ã, ÅðÇ༺ ±Ù½Ã, ÁøÇ༺ ±Ù½Ã·Î ±¸ºÐµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº °­µµ ±Ù½Ã ºÐ¾ß°¡ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù.

Ä¡·á Ãø¸é¿¡¼­ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦, ÄÜÅÃÆ®·»Áî, °¢¸·±¼Àý±³Á¤¼ú, ±¼Àý±³Á¤¼ö¼ú·Î ±¸ºÐµË´Ï´Ù. Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾ÈÁ¦ ºÎ¹®Àº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ, ±¼Àý ¼ö¼ú ºÎ¹®Àº ¶ó½Ä ¹× PRK·Î ¼¼ºÐÈ­µË´Ï´Ù.

¿¬·É´ëº°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº ¼ºÀÎ ±Ù½Ã¿Í ¼Ò¾Æ ±Ù½Ã·Î ³ª´¹´Ï´Ù. ¼ºÀÎ ±Ù½Ã ºÎ¹®Àº 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ ´õ Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚ¿¡ µû¶ó ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, Àü¹® Ŭ¸®´Ð, ±¼Àý ±³Á¤ ¼ö¼ú¼¾ÅÍ·Î ºÐ·ùµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº º´¿ø ¹× Ŭ¸®´Ð ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

±¹°¡º°·Î ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀåÀº È£ÁÖ, Áß±¹, ÀϺ», ÀϺ», Àεµ, Çѱ¹ ¹× ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ºÐ·ùµÇ¸ç, 2022³â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå Á¡À¯À²Àº Áß±¹ÀÌ µ¶Á¡Çß½À´Ï´Ù.

Bausch Health Companies Inc, Alcon AG, CooperVision Inc, Johnson &Johnson Vision Care Inc, Nidek Co Ltd, Haag-Streit AG, Carl Zeiss AG´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷µéÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ±¸µµ

  • PEST ºÐ¼®
  • ±â¾÷ Á¡À¯À² ºÐ¼®

Á¦5Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ÇâÈÄ µ¿Çâ
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå ±Ù½Ã Ä¡·á ½ÃÀå-¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®

Á¦7Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : À¯Çüº°

  • °­µµ ±Ù½Ã
  • º¯¼º ±Ù½Ã
  • ÁøÇ༺ ±Ù½Ã

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : Ä¡·á¹ýº°

  • Àú¿ë·® ¾ÆÆ®·ÎÇÉ Á¡¾È¾×
  • ±¼Àý ±³Á¤ ¼ö¼ú
  • ÄÜÅÃÆ®·»Áî
  • Ortho-K

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : ¿¬·ÉÃþº°

  • ¼ºÀÎ ±Ù½Ã
  • ¼Ò¾Æ ±Ù½Ã

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø ¹× Ŭ¸®´Ð
  • Àü¹® Ŭ¸®´Ð
  • ±¼Àý±³Á¤ ¼ö¼ú¼¾ÅÍ

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ±Ù½Ã Ä¡·á ½ÃÀå : ±¹°¡º° ºÐ¼®

  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç

Á¦12Àå ¾÷°è »óȲ

  • ±Ù½Ã Ä¡·á ½ÃÀå ¼ºÀå Àü·«
  • À¯±âÀû ¼ºÀå Àü·«
  • ¹«±âÀû ¼ºÀå Àü·«
    • ¼ºÀå Àü·«

Á¦13Àå ±â¾÷ °³¿ä

  • Bausch Health Companies Inc
  • Alcon AG
  • CooperVision Inc
  • Johnson & Johnson Vision Care Inc
  • Nidek Co Ltd
  • Haag-Streit AG
  • Carl Zeiss AG

Á¦14Àå ºÎ·Ï

LSH 24.10.31

The Asia Pacific myopia treatment market was valued at US$ 3,097.16 million in 2022 and is expected to reach US$ 6,348.64 million by 2030; it is estimated to register a CAGR of 9.4% from 2022 to 2030.

Rising Availability of Advanced Technologies for Treating the Targeted Myopia Boosts Asia Pacific Myopia Treatment Market

The rising availability of advanced technologies for treating targeted myopia is a significant opportunity for the myopia treatment market. Advances in technologies such as laser-assisted in-situ keratomileusis (LASIK), photorefractive keratectomy (PRK), and implantable collamer lenses (ICL) have made it possible to correct myopia more effectively and with fewer complications. Various ground-breaking data were also presented during the congress; over 30 abstracts backed by Johnson & Johnson Vision have been approved for presentation. Surgeons can apply the innovative SILK (i.e., Smooth Incision Lenticule Keratomileusis) treatment to treat myopic patients who have astigmatism or do not utilize the ELITATM Platform. The ELITATM Platform offers surgeons an exceptionally smooth and uncomplicated lenticular removal procedure with next-day outcomes and recovery owing to its fast laser delivery technology and ultra-precise laser pulse. These advanced technologies have traditionally been expensive and inaccessible to many patients. Still, as they become more widely available, they present an opportunity for the myopia treatment market to expand its reach and provide better treatment options to a larger patient population. In addition to these advanced technologies, other emerging treatments such as orthokeratology (ortho-k) and atropine eye drops are gaining popularity as effective methods for managing myopia. The popular orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Paragon CRT ortho-k designs, MiSight day soft contact lenses, and SightGlass Vision Diffusion Optics Technology spectacle lenses. These non-invasive treatments can be more affordable than surgical options, making them accessible to a wider range of patients. Overall, the rising availability of advanced technologies for treating targeted myopia presents a significant opportunity for the myopia treatment market. By providing patients with more effective and accessible treatment options, the market can help improve vision health outcomes and address a significant unmet need in the global healthcare landscape.

Asia Pacific Myopia Treatment Market Overview

Asia Pacific myopia treatment market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. This region accounted for over 30.14% of the Asia Pacific myopia treatment market in 2022 owing to the increasing aging population, rising number of research studies, growing government support, and increasing eye-related disorders in the region.

In Asia Pacific, China held the largest market share for Asia Pacific myopia treatment market in 2022. The market growth is primarily attributed to the aging population, the increasing prevalence of myopia, and the rising emphasis on preventive care. For instance, according to a study published by the Population Reference Bureau in 2020, the old-age population of China is expected to reach ~366 million by 2050. Moreover, according to the same estimates, around 26% of China's population will be over 65 by 2050, up from 12% in 2020. Such an extensively increasing geriatric population is anticipated to offer lucrative opportunities for the increased demand for products in the country. The country is also witnessing considerable growth in the prevalence of myopia, particularly in children, which is likely to increase the adoption of treatments in China. For instance, preschoolers and primary and secondary school students in China had a 50.2% prevalence of myopia in 2019, according to the British Journal of Ophthalmology. Additionally, according to the same source, 54.71% of children and adolescents between the ages of 6 and 16 had myopia overall in 2021. Thus, the increasing geriatric population and the increasing prevalence of myopia are driving the market growth.

Asia Pacific Myopia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Myopia Treatment Market Segmentation

The Asia Pacific myopia treatment market is categorized into type, treatment, age group, end user, and country.

Based on type, the Asia Pacific myopia treatment market is segmented into high myopia, degenerative myopia, and progressive myopia. The high myopia segment held the largest Asia Pacific myopia treatment market share in 2022.

In terms of treatment, the Asia Pacific myopia treatment market is segmented into low-dose atropine eye drops, contact lenses, ortho-k, and refractive surgery. The low-dose atropine eye drops segment held the largest Asia Pacific myopia treatment market share in 2022. Furthermore, the refractive surgery segment is subcategorized into LASIK and PRK.

By age group, the Asia Pacific myopia treatment market is bifurcated into adult myopia and childhood myopia. The adult myopia segment held a larger Asia Pacific myopia treatment market share in 2022.

Based on end user, the Asia Pacific myopia treatment market is categorized into hospitals and clinics, specialty clinics, and refractive surgery centers. The hospitals and clinics segment held the largest Asia Pacific myopia treatment market share in 2022.

Based on country, the Asia Pacific myopia treatment market is categorized into Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific myopia treatment market share in 2022.

Bausch Health Companies Inc, Alcon AG, CooperVision Inc, Johnson & Johnson Vision Care Inc, Nidek Co Ltd, Haag-Streit AG, and Carl Zeiss AG are some of the leading companies operating in the Asia Pacific myopia treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Myopia Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Market Share Analysis, By Companies

5. Asia Pacific Myopia Treatment Market - Key Market Dynamics

  • 5.1 Asia Pacific Myopia Treatment Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Myopia
    • 5.2.2 Increased Awareness of Myopia Treatment
  • 5.3 Market Restraints
    • 5.3.1 Lack of Skilled Professionals
  • 5.4 Market Opportunities
    • 5.4.1 Rising Availability of Advanced Technologies for Treating The Targeted Myopia
  • 5.5 Future Trends
    • 5.5.1 Application of Artificial Intelligence in Myopia Treatment
  • 5.6 Impact of Drivers and Restraints:

6. Myopia Treatment Market - Asia Pacific Market Analysis

7. Asia Pacific Myopia Treatment Market Analysis - by Type

  • 7.1 High Myopia
    • 7.1.1 Overview
    • 7.1.2 High Myopia: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Degenerative Myopia
    • 7.2.1 Overview
    • 7.2.2 Degenerative Myopia: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Progressive Myopia
    • 7.3.1 Overview
    • 7.3.2 Progressive Myopia: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Myopia Treatment Market Analysis - by Treatment

  • 8.1 Low-Dose Atropine Eye Drops
    • 8.1.1 Overview
    • 8.1.2 Low-Dose Atropine Eye Drops: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Refractive Surgery
    • 8.2.1 Overview
    • 8.2.2 Refractive Surgery: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
    • 8.2.3 LASIK
    • 8.2.4 PRK
  • 8.3 Contact Lenses
    • 8.3.1 Overview
    • 8.3.2 Contact Lenses: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Ortho-K
    • 8.4.1 Overview
    • 8.4.2 Ortho-K: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Myopia Treatment Market Analysis - by Age Group

  • 9.1 Adult Myopia
    • 9.1.1 Overview
    • 9.1.2 Adult Myopia: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.2 Childhood Myopia
    • 9.2.1 Overview
    • 9.2.2 Childhood Myopia: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Myopia Treatment Market Analysis - by End User

  • 10.1 Hospitals and Clinics
    • 10.1.1 Overview
    • 10.1.2 Hospitals and Clinics: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.2 Specialty Clinics
    • 10.2.1 Overview
    • 10.2.2 Specialty Clinics: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Refractive Surgery Centers
    • 10.3.1 Overview
    • 10.3.2 Refractive Surgery Centers: Asia Pacific Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)

11. Asia Pacific Myopia Treatment Market - Country Analysis

  • 11.1 Asia Pacific
    • 11.1.1 Asia Pacific: Myopia Treatment Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.1 Asia Pacific: Myopia Treatment Market - Revenue and Forecast Analysis - by Country
      • 11.1.1.2 China
      • 11.1.1.3 China: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.3.1 China: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.3.2 China: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.3.3 China: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.3.4 China: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.3.5 China: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.4 Japan
      • 11.1.1.5 Japan: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.5.1 Japan: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.5.2 Japan: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.5.3 Japan: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.5.4 Japan: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.5.5 Japan: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.6 India
      • 11.1.1.7 India: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.7.1 India: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.7.2 India: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.7.3 India: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.7.4 India: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.7.5 India: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.8 Australia
      • 11.1.1.9 Australia: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.9.1 Australia: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.9.2 Australia: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.9.3 Australia: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.9.4 Australia: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.9.5 Australia: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.10 South Korea
      • 11.1.1.11 South Korea: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.11.1 South Korea: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.11.2 South Korea: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.11.3 South Korea: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.11.4 South Korea: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.11.5 South Korea: Myopia Treatment Market Breakdown, by End User
      • 11.1.1.12 Rest of Asia Pacific
      • 11.1.1.13 Rest of Asia Pacific: Myopia Treatment Market - Revenue and Forecast to 2030 (US$ Million)
        • 11.1.1.13.1 Rest of Asia Pacific: Myopia Treatment Market Breakdown, by Type
        • 11.1.1.13.2 Rest of Asia Pacific: Myopia Treatment Market Breakdown, by Treatment
        • 11.1.1.13.3 Rest of Asia Pacific: Myopia Treatment Market Breakdown, by Refractive Surgery
        • 11.1.1.13.4 Rest of Asia Pacific: Myopia Treatment Market Breakdown, by Age Group
        • 11.1.1.13.5 Rest of Asia Pacific: Myopia Treatment Market Breakdown, by End User

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in Myopia Treatment Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Bausch Health Companies Inc
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Alcon AG
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 CooperVision Inc
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Johnson & Johnson Vision Care Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 Nidek Co Ltd
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Haag-Streit AG
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 Carl Zeiss AG
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦